Sarcomas are a diverse group of cancers that form in bones and soft tissues like muscles, joints, tendons and fat. More than 70 subtypes exist, many of them quite rare.
At Fred Hutch, we’re studying how sarcomas develop, how they evade the body’s defenses and how to trigger the immune system to fight them.
Sarcoma research at Fred Hutch covers every aspect of the disease’s biology and treatment in children and adults. We study how sarcomas develop, how they respond to various therapies and how we can enhance the immune response against them.
We’re world leaders in harnessing the immune system to attack cancer. A prime example is T-cell therapy, which deploys a specialized type of immune cell, the T cell. Hutch scientists are reprogramming patients’ own T cells to better recognize and target telltale markers on sarcomas. We run clinical trials that are combining radiation treatment with these T-cell therapies. And we test drugs called checkpoint inhibitors, which take the brakes off a patient’s immune system so it mounts a better response against sarcomas.
We’re studying new drugs that target substances on or in sarcoma cells and disrupt their ability to grow and spread.
Dr. Elizabeth Loggers divides her time between caring for patients with all forms of sarcoma and conducting research to identify new treatments for rare forms of the cancer. Her research includes improving models of health care delivery and patient communication, particularly for patients with advanced cancer, with the goal of optimizing the patient and family experience.
Clinical research is an essential part of the scientific process that leads to new treatments and better care. Clinical trials can also be a way for patients to get early access to new cutting-edge new therapies. Our clinical research teams are running clinical studies on various kinds of sarcoma.
Our interdisciplinary scientists and clinicians work together to prevent, diagnose and treat sarcoma as well as other cancers and diseases.
Seattle Cancer Care Alliance, our clinical care partner, gives patients access to the comprehensive, world-class treatments developed at Fred Hutch.
When Sarah Nabaggala first noticed itchy brown spots on her skin, she thought she might have malaria, which is common in her tropical home city of Entebbe, Uganda. After a blood test proved negative, she went to a skin clinic, where doctors did a biopsy. She was diagnosed with Kaposi sarcoma, which is among the nearly 20 percent of cancers worldwide that are caused by infectious pathogens.